Merck (MRK) Q3 earnings report 2023

Merck headquarters in Rahway, New Jersey, on Tuesday, April 18, 2023.Christopher Occhicone | Bloomberg | Getty ImagesMerck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations on strong sales of its blockbuster cancer drug Keytruda, HPV vaccine Gardasil and surprisingly, its Covid drug Lagevrio. The pharmaceutical giant also...

Read more...

Bristol Myers Squibb (BMY) Q3 earnings report 2023

Bristol Myers Squibb on Thursday reported quarterly adjusted earnings that topped expectations and posted revenue in line with estimates, even as sales of the company's popular blood cancer drug Revlimid plummeted due to generic competition. Bristol Myers, one of the world's largest pharmaceutical companies, raked in $10.96 billion in revenue...

Read more...

Alzheimer’s drug Leqembi shows promise as injection

Eisai on Wednesday said an injectable version of the Alzheimer's drug Leqembi showed promising initial results in a clinical trial, potentially paving the way for a new and more convenient option for administering the antibody treatment. However, the injection did not cause lower rates of brain swelling and bleeding, which...

Read more...

GSK RSV vaccine shows potential to protect adults 50 to 59

A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday.The initial trial results suggest that GSK's shot, known as Arexvy, could help protect a wider population from RSV, a disease that causes...

Read more...

Sanofi to offer insulin for $35 to Americans through GoodRx

Sanofi Lantus brand insulin pens are arranged for a photograph in Brooklyn, New York, on April 5, 2019.Alex Flynn | Bloomberg | Getty ImagesAmericans, regardless of their insurance status, can now access Sanofi's most widely prescribed insulin for $35 through the prescription drug savings company GoodRx, the companies announced...

Read more...

Pfizer to price Covid drug Paxlovid at $1,390 per course

Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken October 7, 2022.Wolfgang Rattay | ReutersPfizer will price a five-day course of its Covid antiviral drug Paxlovid at $1,390 when the company starts to transition it to the commercial market later this...

Read more...